Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4508779 | 0.88 | RAB9A (0.48) | CPB2LMNAFAAH | |
| SCHEMBL4009042 | 0.81 | CPB2 (0.64) | CPB2CPB1 | |
| SCHEMBL4507391 | 0.80 | CPB2 (0.63) | CPB2CPB1 | |
| SCHEMBL4515230 | 0.80 | CPB2 (0.57) | CPB2CPB1 | |
| SCHEMBL4521167 | 0.80 | CPB2 (0.57) | CPB2CPB1 | |
| SCHEMBL4510175 | 0.80 | CPB2 (0.62) | CPB2CPB1 | |
| SCHEMBL4509644 | 0.79 | CPB2 (0.65) | CPB2CPB1 | |
| SCHEMBL4512112 | 0.79 | CPB2 (0.56) | CPB2CPB1 | |
| SCHEMBL4508225 | 0.79 | CPB2 (0.56) | CPB2CPB1 | |
| SCHEMBL4503501 | 0.79 | CPB2 (0.58) | CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572817-B2 | 2,5-disubstituted 3-mercaptopentanoic acid | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | claimed |
| US-7572817-B2 | 2,5-disubstituted 3-mercaptopentanoic acid | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| EP-1532111-B1 | 2,5-DISUBSTITUTED 3-MERCAPTOPENTANOIC ACID | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | EP | disclosed |
| US-20050176780-A1 | 2,5-disubstituted 3-mercaptopentanoic acid | ASTRAZENECA AB (SE) | 2005-08-11 | — | — | US | disclosed |
| EP-1532111-A1 | 2,5-DISUBSTITUTED 3-MERCAPTOPENTANOIC ACID | AstraZeneca AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2003106420-A1 | 2,5-DISUBSTITUTED 3-MERCAPTOPENTANOIC ACID | ASTRAZENECA AB (SE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176780-A1 | 2,5-disubstituted 3-mercaptopentanoic acid | METAP1, MPST, DNPEP | CPB2 26/4885LMNA 4279/4885ALDH1A1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.